The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.
What Market Size Is Forecasted For The Protein Degradation Therapy Market By 2030 Based On Its 2026 Value?
The protein degradation therapy market has demonstrated robust expansion over recent years. This market is anticipated to expand from $1.25 billion in 2025 to $1.35 billion in 2026, reflecting a compound annual growth rate (CAGR) of 8.1%. Key factors contributing to this historical growth include advancements in molecular biology research, the broadening of targeted cancer therapies, enhanced comprehension of protein dysfunction in various diseases, initial clinical achievements, and increasing venture capital investment in the biotechnology sector.
The protein degradation therapy market is anticipated to experience substantial expansion in the coming years. This market is projected to reach $1.83 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.8%. Factors contributing to this growth over the forecast period include a heightened demand for new cancer treatments, increased capital flowing into precision oncology, the broadening of protein degradation platforms, an uptick in clinical trial engagement, and enhanced regulatory backing for pioneering therapeutics. Key trends anticipated during this period involve the intensified creation of targeted protein degraders, a sharpened focus on applications within oncology, greater financial commitment to PROTAC-based treatments, an enlarging pool of clinical pipeline candidates, and strengthened partnerships between pharmaceutical and biotechnology companies.
Download A Free Sample Report For Comprehensive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20603&type=smp
What Key Growth Drivers Are Influencing The Protein Degradation Therapy Market?
The increasing prevalence of cancer is anticipated to stimulate the growth of the protein degradation therapy market moving forward. Cancer refers to a collection of diseases distinguished by the uncontrolled multiplication and spread of abnormal cells within the body. The escalation in cancer rates primarily stems from a confluence of factors, with the aging population playing a crucial role. Furthermore, lifestyle elements such as smoking, an unhealthy diet, insufficient physical activity, and rising obesity levels have heightened the susceptibility to various cancers. Protein degradation therapy is vital for treating cancer because it specifically targets and eradicates proteins that fuel cancer progression and survival, potentially overcoming resistance to conventional treatments. For instance, in February 2024, a report from the World Health Organization, a Switzerland-based intergovernmental organization, indicated that over 35 million new cancer cases are expected in 2050, representing a 77% increase from the estimated 20 million cases in 2022. Moreover, high human development index (HDI) countries are projected to witness the largest rise in absolute numbers, with an additional 4.8 million new cases predicted in 2050 compared with 2022 estimates. Hence, the increasing burden of cancer is propelling the growth of the protein degradation therapy market.
How Is The Protein Degradation Therapy Market Distributed Across Key Segments?
The protein degradation therapy market covered in this report is segmented –
1) By Type: Bavdegalutamide (ARV – 110), Vepdegestrant (ARV – 471)
2) By Application: Oncology, Neurodegenerative Diseases, Infectious Diseases, Other Applications
3) By End-User: Pharmaceutical Companies, Biotechnology Companies, Academic And Research Institutes
Subsegments:
1) By Bavdegalutamide (ARV-110): Androgen Receptor Degraders, Prostate Cancer Therapy
2) By Vepdegestrant (ARV-471): Estrogen Receptor Degraders, Breast Cancer Therapy
Which Trends Are Influencing The Expansion Of The Protein Degradation Therapy Market?
Major companies active within the protein degradation therapy market are increasingly adopting strategic partnerships. This approach aims to foster the creation of innovative therapies, leverage complementary expertise, share resources, and accelerate the discovery and development of new drug candidates that target disease-causing proteins. These collaborations involve companies utilizing each other’s strengths and resources to gain mutual benefits and achieve shared success. For instance, in February 2024, Arvinas, a U.S.-based biotechnology company, introduced its first oral PROTAC degrader (ARV-102), which is designed to cross the blood-brain barrier and target LRRK2 for neurodegenerative disease applications. The ARV-102 molecule features oral bioavailability, a brain-penetrant profile, and high specificity for LRRK2. This innovation strengthens companies’ pipelines by addressing previously undruggable targets, though challenges remain around long-term safety, manufacturing complexity, and optimization of pharmacokinetics given its larger molecular structure.
Which Companies Are Influencing The Protein Degradation Therapy Market?
Major companies operating in the protein degradation therapy market are Relay Therapeutics, Arvinas Holding Company LLC, Kymera Therapeutics, Nurix Therapeutics, Vividion Therapeutics, Mission Therapeutics Ltd., C4 Therapeutics Inc., Cullgen Inc., Frontier Medicines, Foghorn Therapeutics, Aileron Therapeutics, Ribometrix Inc., Nimbus Therapeutics, Jnana Therapeutics, KSQ Therapeutics, Stoke Therapeutics, Flare Therapeutics, Accent Therapeutics, Monte Rosa Therapeutics, Lycia Therapeutics, Dialectic Therapeutics, Amphista Therapeutics, Biotheryx Inc., Cedilla Therapeutics, Dewpoint Therapeutics Inc
Access The Complete Protein Degradation Therapy Market Report:
https://www.thebusinessresearchcompany.com/report/protein-degradation-therapy-global-market-report
Which Regional Market Leads The Protein Degradation Therapy Market?
North America was the largest region in the protein degradation therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the protein degradation therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Access Protein Degradation Therapy Market Report for Deeper Competitive Insights
https://www.thebusinessresearchcompany.com/sample.aspx?id=20603&type=smp
Browse Through More Reports Similar to the Global Protein Degradation Therapy Market 2026, By The Business Research Company
Home Infusion Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/home-infusion-therapy-global-market-report
Car T Therapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/car-t-therapy-global-market-report
Aromatherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/aromatherapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model